[theold]

The decision was based on the agency’s clinical trial results involving 550 children between 6 and 11, which showed that the vaccine provided immunogenicity for 96 percent of the recipient pool and offered similar efficacy scores to previous trials for children over 12 years old.

https://www.thejakartapost.com/indonesia...to-11.html